A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-Bâ„¢), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-Bâ„¢), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
Key Inclusion Criteria:
Key Exclusion Criteria:
Rosario, S2000PBJ, Argentina
São Paulo, 04039-901, Brazil
Bogota, Cundinamarca, Colombia
Bucaramanga, Santander Department, Colombia
Hyderabaad, 500 003, India
Hyderabaad, 500 082, India
Bucharest, 020125, Romania
Haulien, 970, Taiwan
Kaosiung, 833, Taiwan
Tau-Yuan County, 333, Taiwan